Complementary medicine use and its cost in Australians with type 2 diabetes: The Fremantle Diabetes Study Phase II

Tatsiana Yarash; Imrana Sharif; Farhat Masood; Rhonda M Clifford; Wendy Davis; Timothy M E Davis

doi:10.1111/imj.14437

Complementary medicine use and its cost in Australians with type 2 diabetes: The Fremantle Diabetes Study Phase II

Tatsiana Yarash, Imrana Sharif, Farhat Masood, Rhonda M Clifford, Wendy Davis, Timothy M E Davis

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

BACKGROUND: Few studies have examined complementary medicine (CM) use in diabetes. Australian data are inconsistent, limited in scope and have not considered cost.

AIMS: To evaluate the prevalence, associates and costs of CMs in a contemporary Australian urban, community-based cohort of people with type 2 diabetes.

METHODS: Baseline CM use was determined as part of a detailed assessment in 1,543 of 1,551 FDS2 participants with type 2 diabetes (mean age 65.7 years, 51.8% males, median diabetes duration 9.0 years) recruited to the Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011 who self-reported medication use including CMs defined as non-prescription medicinal products.

RESULTS: 672 FDS2 type 2 participants (43.6%) used at least one type of CM, 92% of which were nutritional supplements (omega-3 fatty acids/fish oil in 24% of CM users followed by calcium in 11%, glucosamine in 10%, and others in <10%). Independent associates of CM use included older age, female sex, any mobility problem, and, inversely, Southern European or Indigenous Australian background, lack of English fluency, ex-/current smoking status, taking oral glucose-lowering medications, and higher HbA1c . The total annual estimated cost of CM used by FDS2 participants with type 2 diabetes was A$121,640 or A$79±208 per person (range A$0-2,993). Extrapolating these data, the 1 million Australians with type 2 diabetes spend A$79 million/year on CMs.

CONCLUSIONS: CM use in type 2 diabetes is both common and costly. Healthcare professionals should consider discussing safe and cost-effective use of CM with their patients with type 2 diabetes. This article is protected by copyright. All rights reserved.

Original language	English
Pages (from-to)	944-950
Number of pages	7
Journal	Internal Medicine Journal
Volume	50
Issue number	8
Early online date	17 Jul 2019
DOIs	https://doi.org/10.1111/imj.14437
Publication status	Published - 1 Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.14437

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications & Cost
Davis, T. (Investigator 01), Bruce, D. (Investigator 02), Davis, W. (Investigator 03), Chubb, S. (Investigator 04), Starkstein, S. (Investigator 05), Clarke, P. (Investigator 06), McAullay, D. (Investigator 07) & Norman, P. (Investigator 08)
NHMRC National Health and Medical Research Council
1/01/13 → 31/12/18
Project: Research
The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications and Cost
Davis, T. (Chief Investigator), Bruce, D. (Chief Investigator), Davis, W. (Chief Investigator), Davis, E. (Chief Investigator), Geelhoed, E. (Chief Investigator) & Knuiman, M. (Chief Investigator)
NHMRC Project Grants
1/01/08 → 31/12/12
Project: Research

Cite this

@article{6e112544faa64b0b9b2ae22628a81301,

title = "Complementary medicine use and its cost in Australians with type 2 diabetes: The Fremantle Diabetes Study Phase II",

abstract = "BACKGROUND: Few studies have examined complementary medicine (CM) use in diabetes. Australian data are inconsistent, limited in scope and have not considered cost.AIMS: To evaluate the prevalence, associates and costs of CMs in a contemporary Australian urban, community-based cohort of people with type 2 diabetes.METHODS: Baseline CM use was determined as part of a detailed assessment in 1,543 of 1,551 FDS2 participants with type 2 diabetes (mean age 65.7 years, 51.8% males, median diabetes duration 9.0 years) recruited to the Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011 who self-reported medication use including CMs defined as non-prescription medicinal products.RESULTS: 672 FDS2 type 2 participants (43.6%) used at least one type of CM, 92% of which were nutritional supplements (omega-3 fatty acids/fish oil in 24% of CM users followed by calcium in 11%, glucosamine in 10%, and others in <10%). Independent associates of CM use included older age, female sex, any mobility problem, and, inversely, Southern European or Indigenous Australian background, lack of English fluency, ex-/current smoking status, taking oral glucose-lowering medications, and higher HbA1c . The total annual estimated cost of CM used by FDS2 participants with type 2 diabetes was A$121,640 or A$79±208 per person (range A$0-2,993). Extrapolating these data, the 1 million Australians with type 2 diabetes spend A$79 million/year on CMs.CONCLUSIONS: CM use in type 2 diabetes is both common and costly. Healthcare professionals should consider discussing safe and cost-effective use of CM with their patients with type 2 diabetes. This article is protected by copyright. All rights reserved.",

author = "Tatsiana Yarash and Imrana Sharif and Farhat Masood and Clifford, {Rhonda M} and Wendy Davis and Davis, {Timothy M E}",

year = "2020",

month = aug,

day = "1",

doi = "10.1111/imj.14437",

language = "English",

volume = "50",

pages = "944--950",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley & Sons",

number = "8",

}

TY - JOUR

T1 - Complementary medicine use and its cost in Australians with type 2 diabetes

T2 - The Fremantle Diabetes Study Phase II

AU - Yarash, Tatsiana

AU - Sharif, Imrana

AU - Masood, Farhat

AU - Clifford, Rhonda M

AU - Davis, Wendy

AU - Davis, Timothy M E

PY - 2020/8/1

Y1 - 2020/8/1

N2 - BACKGROUND: Few studies have examined complementary medicine (CM) use in diabetes. Australian data are inconsistent, limited in scope and have not considered cost.AIMS: To evaluate the prevalence, associates and costs of CMs in a contemporary Australian urban, community-based cohort of people with type 2 diabetes.METHODS: Baseline CM use was determined as part of a detailed assessment in 1,543 of 1,551 FDS2 participants with type 2 diabetes (mean age 65.7 years, 51.8% males, median diabetes duration 9.0 years) recruited to the Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011 who self-reported medication use including CMs defined as non-prescription medicinal products.RESULTS: 672 FDS2 type 2 participants (43.6%) used at least one type of CM, 92% of which were nutritional supplements (omega-3 fatty acids/fish oil in 24% of CM users followed by calcium in 11%, glucosamine in 10%, and others in <10%). Independent associates of CM use included older age, female sex, any mobility problem, and, inversely, Southern European or Indigenous Australian background, lack of English fluency, ex-/current smoking status, taking oral glucose-lowering medications, and higher HbA1c . The total annual estimated cost of CM used by FDS2 participants with type 2 diabetes was A$121,640 or A$79±208 per person (range A$0-2,993). Extrapolating these data, the 1 million Australians with type 2 diabetes spend A$79 million/year on CMs.CONCLUSIONS: CM use in type 2 diabetes is both common and costly. Healthcare professionals should consider discussing safe and cost-effective use of CM with their patients with type 2 diabetes. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Few studies have examined complementary medicine (CM) use in diabetes. Australian data are inconsistent, limited in scope and have not considered cost.AIMS: To evaluate the prevalence, associates and costs of CMs in a contemporary Australian urban, community-based cohort of people with type 2 diabetes.METHODS: Baseline CM use was determined as part of a detailed assessment in 1,543 of 1,551 FDS2 participants with type 2 diabetes (mean age 65.7 years, 51.8% males, median diabetes duration 9.0 years) recruited to the Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011 who self-reported medication use including CMs defined as non-prescription medicinal products.RESULTS: 672 FDS2 type 2 participants (43.6%) used at least one type of CM, 92% of which were nutritional supplements (omega-3 fatty acids/fish oil in 24% of CM users followed by calcium in 11%, glucosamine in 10%, and others in <10%). Independent associates of CM use included older age, female sex, any mobility problem, and, inversely, Southern European or Indigenous Australian background, lack of English fluency, ex-/current smoking status, taking oral glucose-lowering medications, and higher HbA1c . The total annual estimated cost of CM used by FDS2 participants with type 2 diabetes was A$121,640 or A$79±208 per person (range A$0-2,993). Extrapolating these data, the 1 million Australians with type 2 diabetes spend A$79 million/year on CMs.CONCLUSIONS: CM use in type 2 diabetes is both common and costly. Healthcare professionals should consider discussing safe and cost-effective use of CM with their patients with type 2 diabetes. This article is protected by copyright. All rights reserved.

U2 - 10.1111/imj.14437

DO - 10.1111/imj.14437

M3 - Article

C2 - 31314167

SN - 1444-0903

VL - 50

SP - 944

EP - 950

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 8

ER -

Complementary medicine use and its cost in Australians with type 2 diabetes: The Fremantle Diabetes Study Phase II

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications & Cost

The Fremantle Diabetes Study Phase II - A Community Based Study of Diabetes Care Control Complications and Cost

Cite this